Can tesamorelin be obtained in Ontario by prescription?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Tesamorelin Availability in Ontario

Tesamorelin is FDA-approved in the United States for HIV-associated lipodystrophy, but there is no evidence in the provided literature that it is available by prescription through Ontario's provincial formulary or covered under the Ontario Drug Benefit program.

Key Findings

Regulatory Status

  • Tesamorelin (Egrifta) received FDA approval in November 2010 specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy 1
  • The drug is a synthetic growth hormone-releasing hormone analogue that stimulates endogenous growth hormone release 2

Ontario Formulary Context

The provided evidence discusses Ontario's pharmaceutical coverage policies but does not mention tesamorelin at all 3. The guideline evidence focuses on SGLT-2 inhibitors and GLP-1 agonists for diabetes management, noting that Ontario and other Canadian provinces have restrictive formulary requirements for various medications 3.

Clinical Evidence Base

Tesamorelin has demonstrated efficacy in:

  • Reducing visceral adipose tissue by approximately 15-25% in HIV patients with central fat accumulation 4, 5, 6
  • Improving lipid profiles (triglycerides, cholesterol ratios) 4, 5
  • Maintaining benefits through 52 weeks of continuous treatment 5
  • Effectiveness even in patients on modern integrase inhibitor-based HIV regimens 7

Important Caveats

The absence of tesamorelin from Ontario formulary discussions suggests it is likely not covered under provincial drug programs, even though it has established efficacy for HIV-associated lipodystrophy. Given Ontario's documented restrictive approach to formulary coverage for other therapeutic agents 3, patients seeking tesamorelin would likely need to:

  • Obtain it through private insurance coverage
  • Pay out-of-pocket costs
  • Seek special authorization or compassionate access programs through Health Canada

The drug label information provided 8 appears to be for a different medication (likely a cough suppressant based on the MAOI warnings), not tesamorelin, and should be disregarded.

References

1
Research

Tesamorelin.

Nature reviews. Drug discovery, 2011

Related Questions

Will tesamorelin be effective after 12 weeks in an adult with HIV‑associated abdominal fat accumulation who is on a stable antiretroviral regimen and has no uncontrolled diabetes or active malignancy?
In an adult with HIV‑associated abdominal fat accumulation who meets waist or BMI criteria, is on a stable antiretroviral regimen, and has no uncontrolled diabetes or active malignancy, should tesamorelin be started at 0.5 mg and titrated upward slowly to avoid a rapid rise in insulin‑like growth factor‑1 (IGF‑1) levels?
What are the evidence‑based guidelines for using tesamorelin in adults with HIV‑associated abdominal fat accumulation who are on a stable antiretroviral regimen, have a waist circumference ≥100 cm (or BMI ≥30 kg/m²), and do not have uncontrolled diabetes or active malignancy?
What are the most common side effects of tesamorelin?
In a reproductive‑aged woman receiving tesamorelin (2 mg subcutaneously daily), can the medication cause her menstrual periods to occur earlier than usual?
What is the most common cause of postprandial vomiting in elderly patients?
How should hyperandrogenism causing chin hair in a female be evaluated and managed?
What are the differential diagnoses for a patient presenting with chest pain, fever, sore throat, and headache?
What does a blood urea nitrogen (BUN) to creatinine ratio of 8 indicate?
Is it appropriate to prescribe ranitidine, and what safer alternatives should be used?
For a patient with severe flight anxiety on a 6‑hour flight who is currently prescribed clonazepam 1 mg as needed but finds it insufficient, what dose should be increased to?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.